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We tested for the presence of coronary calcifications in
patients with chronic renal disease not on dialysis and
studied its progression in 181 consecutive non-dialyzed
patients who were followed for a median of 745 days.
Coronary calcifications (calcium score) were tallied in
Agatston units by computed tomography, and the patients
were stratified into two groups by their baseline calcium
score (100U or less and over 100U). Survival was measured
by baseline calcium score and its progression. Cardiac death
and myocardial infarction occurred in 29 patients and were
significantly more frequent in those patients with calcium
scores over 100U (hazard ratio of 4.11). With a calcium score
of 100U or less, the hazard ratio for cardiac events was 0.41
and 3.26 in patients with absent and accelerated progression,
respectively. Thus, in non-dialyzed patients, the extent of
coronary calcifications was associated to cardiac events, and
progression was an independent predictive factor of cardiac
events mainly in less calcified patients. Hence, assessment of
coronary calcifications and progression might be useful for
earlier management of risk factors and guiding decisions for
prevention of cardiac events in this patient population.
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In incident and prevalent patients on dialysis, vascular
calciﬁcations are frequent. The results of the ﬁrst seminal
report showing that dialysis patients have remarkably higher
incidence of coronary artery, mitral, and aortic valve calci-
ﬁcation
1 have been repeatedly conﬁrmed in recent years;
hence, latest guidelines have included the detection of extra
osseous calciﬁcation as a test for diagnosing mineral and
bone disorders in chronic kidney disease (CKD).
2
Vascular calciﬁcations, namely, coronary artery calciﬁca-
tions (CACs), are regarded as markers of severe vasculo-
pathy
1–5 and strong predictors of cardiovascular events.
2,4–6
Importantly, both in young
7 and adult dialysis patients,
1,6,8,9
calciﬁcations progress more rapidly than in controls; the
progression is an additional independent factor responsible
for cardiovascular events.
CACs are present even in patients at early stages of
CKD (CKD patients). Indeed, CACs were found in almost
one half of non-diabetic predialysis patients (CKD
stages 3–5);
10 higher prevalence of CAC in CKD patients
compared with controls has been subsequently conﬁrmed
by larger studies that have included diabetic CKD
patients.
11–14
Faster progression of calciﬁcations has been observed in
CKD patients;
15–19 the underlying mechanisms are still not
well determined. In fact, although in dialysis patients, the
progression of calciﬁcation seems to be linked to deranged
mineral metabolism,
7–9 in CKD patients, this link has not
been conﬁrmed
15–17,19 despite faster progression of CAC
occurred in patients with high-normal serum phosphorus
15
and progression was reduced by binding the ion.
16
Mild-to-moderate elevations in serum creatinine levels are
associated with increased rates of all-cause
20,21 and cardio-
vascular mortality.
20,22,23 Thus, CKD patients are more
exposed to risk of mortality than to start renal replacement
therapy.
24,25 Multiple possible explanations exist for the
association between CKD and increased mortality. Reduced
kidney function is associated with independent and strong
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levels, elevated plasma homocysteine, enhanced coagulability,
anemia, left ventricular hypertrophy, and endothelial dys-
function.
22,24–26
The aim of the present study is to ascertain a potential
association between the presence and progression of CAC
with cardiac events in CKD-patients not on dialysis. This
association has never been evaluated before.
RESULTS
Study population
The initial cohort consisted of 188 consecutive asymptomatic
CKD patients who fulﬁlled the inclusion criteria. Seven
patients (3.7%) were lost at the follow-up: three moved
to another clinic and four withdrew the consent; thus, the
ﬁnal cohort was represented by 181 patients. No racial/
ethnic-based differences were present. In the whole-cohort
study, kidney diseases were: glomerulonephritis 27%
(20.5–33.6, conﬁdence interval, CI), ischemic nephropathy
11% (6.4–15.7, CI), biopsy-proven diabetic nephropathy
8.3% (4.2–12.3, CI), and other diseases 28.8% (19.5–32.4, CI);
renal disease was unknown in the remaining cases. Median
duration of diabetes was 174 months (48–228, interquartile
range, IQR); hypertension was present in 95.6% (92.6–98.6,
CI), with a median duration of 72 months (32–130, IQR).
Patients were followed-up for a median time of 745 days
(403–1078, IQR).
During the observation, time-measured creatinine clearance
remained stable and no patient required dialysis treatment.
At baseline, CACs were found in 54.7% (47.4–61–9, CI) of
the whole study population. Among males and females, there
was no signiﬁcant difference in incidence of calciﬁcation
(56.8% (40.8–72.7, CI) and 55.5% (47.4–63.7, CI), respec-
tively) and median CAC score (107 Agatston unit (AU;
36–145.5, IQR) and 168AU (72.7–341.2, IQR), respectively).
Median CAC score was 109AU (55–220, IQR), 153AU
(37–257, IQR), 177AU (87–454, IQR), and 168AU (84–311,
IQR) in patients at stages 2, 3, 4, and 5, respectively.
Patients were divided in two groups (p100 and
4100AU) according to baseline CAC score. The median
interval between ﬁrst multislice computed tomography
(MSCT) and cardiac event or end of the study was 689 days
(410–922, IQR) and 820 days (380–1178, IQR) in patients
with CAC score p100 and 4100AU, respectively. Baseline
characteristics of the two groups are reported in Table 1.
Patients with CAC score p100AU (range: 0–98; mean:
14.6±27.3 (s.d.); and median: 0 (0–17, IQR)) were 119;
patients with CAC score 4100AU (range: 105–2860; mean:
384.7±453.8 (s.d.); and median: 234 (163–430, IQR)) were
62. CAC score was 41000AU in four patients of the latter
group. Patients with CAC score 4100AU were more likely to
be older (P¼0.0001) and to have diabetes (28.8% (17.1–40.6,
CI) versus 7.6% (2.8–12.4, CI; Po0.0002)), hypertension (100
versus 93.3% (88.8–97.8, CI; P¼0.0368)), longer duration of
hypertension (median duration: 120 months (48–170, IQR)
versus 62 months (24–120, IQR); Po0.005).
No signiﬁcant differences were observed between other
variables of the two groups. In particular, there was no
difference in measured creatinine clearance, in variables of
mineral metabolism (intact parathyroid hormone, serum
calcium, and phosphorus), lipids (total cholesterol, triglycer-
ides, high-density lipoprotein cholesterol, and low-density
lipoprotein cholesterol), inﬂammation (homocysteine, ﬁbrin-
ogen, and high-sensitivity C-reactive protein), nutrition
(total protein and serum albumin), and anemia (hematocrit).
Furthermore, no signiﬁcant difference was found in therapy
with calcium channel blockers, statins, and phosphate
binders.
During the observation time, 29 patients (16%) had a
cardiac event (cardiac death or myocardial infarction). The
events occurred more frequently in patients with CAC score
4100AU (27.5% (16.2–38.7, CI)) than in those with CAC
score p100AU (7.6% (2.7–12.4, CI); P¼0.0003); in the
former group, the hazard risk (HR) for cardiac events was
4.11 (1.77–9.57, CI; Po0.0006).
Association between baseline CAC score and survival is
shown in Figure 1. After adjustment for age, diabetes,
glomerular ﬁltration rate (GFR) (as 24-h-measured creati-
nine clearance), and hypertension, baseline CAC score
4100AU was a signiﬁcant (P¼0.0017) predictor of cardiac
events.
In the whole study population, survival was also analyzed
on the basis of the annualized progression of CAC score
(absent: 25th percentile; moderate: 25th–75th percentiles; and
accelerated: 475th percentile); the results are shown in
Figure 2. After adjustment for age, diabetes, GFR (as 24-h-
measured creatinine clearance), hypertension, and baseline
CAC score, survival was signiﬁcantly (Po0.0068) worse in
patients with accelerated progression; in patients with absent
or moderate progression, survival curves overlapped.
Finally, survival was assessed in two groups taking in
account both baseline value of CAC score and progression.
With CAC score p100AU, HR for cardiac events was 0.41
and 3.26 in patients with absent and accelerated progression,
respectively; in contrast, with CAC score 4100AU, HR was
4.72 and 2.97 in patients with absent and accelerated
progression, respectively. Therefore, accelerated progression
affected survival of patients with a low baseline CAC score by
a greater extent compared with those with a high one. The
ﬁnal multiple Cox regression model is shown in Table 2.
Among all potential confounders (listed in Table 1), only
diabetes reached a P-value o0.2 and entered into multiple
Cox regression analysis. In this model, baseline CAC score
and progression independently predicted cardiac events. In
addition, stratiﬁcation by both factors (baseline CAC score
and progression) pointed out a possible effect modiﬁcation.
Baseline CAC score 4100AU and accelerated progression
(475th percentile) signiﬁcantly interacted and reduced the
risk of outcomes (HRo1). Because of this interaction, HR
was 4.2 (as a result of 8.4 6.3 0.08) in patients with CAC
score 4100AU and accelerated progression; therefore, it was
lower than that caused by each variable itself.
Kidney International (2011) 80, 112–118 113
D Russo et al: Coronary artery calcification progression and cardiac events original articleDISCUSSION
Large epidemiological studies have reported that CKD
patients are more likely to die than to start renal replacement
therapy.
24,25 CACs are regarded as markers of severe
vasculopathy and strong predictor of cardiovascular mortal-
ity in patients on dialysis.
3–5,26–28 As CACs are present even at
early stages of CKD,
10,11,15–17 it is reasonable to hypothesize
that CAC may be involved in the high mortality occurring
in CKD-patients not on dialysis yet. On this regard, an
associations between severity of CAC and all-cause mortality
and between presence of CAC and combined outcomes have
been evidenced in proteinuric diabetic
29 and non-diabetic
30
CKD patients, respectively. All-cause mortality and combined
outcomes may mask the incidence of cardiac events that are
more strictly dependent on CAC. Therefore, in the present
study, cardiac events such as cardiac death or myocardial
infarction were recorded, and a potential association with
the presence and the progression of CAC was evaluated.
The impact of CAC progression on mortality has never been
evaluated in CKD patients.
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Figure 1|Adjusted survival according to baseline coronary
artery calcification (CAC) score. Multivariable-adjusted (age,
diabetes, GFR, and hypertension) association between baseline
CAC score p100AU (continuous line) and CAC score 4100AU
(dashed line) and survival. Survival was significantly (P¼0.0017)
worse in presence of CAC score 4100AU. AU, Agatston unit
(for scoring CAC); GFR, glomerular filtration rate.
Table 1|Baseline characteristics of patients stratified by CAC score
CAC score p100AU (n=119) CAC score 4100AU (n=62) P
Demographics
Age (years)
a 54 (41–60) 62 (56–68) 0.0001
Female
b 21.9 (14.3–29.3) 17.7 (8.1–27.4) 0.5156
Male
b 78.1 (7.1–85.7) 82.3 (72.6–91.9) 0.5156
Clinical characteristics
Diabetes
b 7.6 (2.8–12.4) 28.8 (17.1–40.6) 0.0002
Hypertension
b 93.3 (88.8–97.8) 100 0.0368
Duration of hypertension (months)
a 63 (24–120) 120 (48–170) 0.005
Laboratory data
a
GFR (ml/s) 0.83 (0.40–1.30) 0.68 (0.40–1.16) 0.3983
Homocysteine (umol/l) 20 (15–29) 19 (14–30) 0.7500
Fibrinogen (mmol/l) 352.0 (300–414) 378.5 (307–406) 0.1767
hsCRP (mg/dl) 0.30 (0.30–0.39) 0.31(0.30–0.42) 0.8079
Hematocrit (%) 40.9 (35.85–44.0) 39.95 (36.55–42.7) 0.7704
iPTH (pg/l) 6.2 (4.3–12.8) 6.2 (4.2–12.6) 0.7347
Calcium (mmol/l) 2.37 (2.27–2.45) 2.40 (2.30–2.50) 0.0586
Phosphorus (mmol/l) 1.2 (1.0–1.4) 1.1 (1.1–1.3) 0.3497
Total serum proteins (g/l) 74 (70–77) 74 (69–77) 0.7980
Serum albumin (g/l) 44 (41–46) 42 (40–46) 0.0755
UAE (mg/24h) 625 (150–1780) 460 (90–2000) 0.5076
Serum bicarbonate (mmol/l) 25 (23–27) 25 (23–27) 0.8477
Total cholesterol (mmol/l) 4.9 (4.4–5.7) 4.8 (4.3–5.5) 0.5878
Triglycerides (mmol/l) 1.4 (1.0–1.9) 1.5 (1.2–2.0) 0.4624
HDL cholesterol (mmol/l) 1.2 (0.9–1.5) 1.2 (1.0–1.5) 0.9226
LDL cholesterol (mmol/l) 2.9 (2.4–3.6) 2.8 (2.3–3.4) 0.3067
Baseline therapy
b
Statins 37.1 (28.2–45.7) 46.8 (34.1–59.4) 0.2022
Calcium channel blockers 38.7 (29.8–47.5) 51.7 (38.7–64.8) 0.0992
Sevelamer 12.6 (6.6–18) 8.3 (1.2–15.4) 0.3918
Other binders 11.8 (5.9–17.6) 5.0 ( 0.6–10.6) 0.0992
Abbreviations: AU, Agatston unit; CAC, coronary artery calcification; CI, confidence interval; GFR, glomerular filtration rate, as 24-h-measured creatinine clearance; HDL, high-
density lipoprotein; hsCRP, high-sensitivity C-reactive protein; iPTH, intact parathyroid hormone; IQR, interquartile range; LDL, low-density lipoprotein; UAE, 24-h urinary
protein excretion.
aData are expressed as median (IQR).
bData are expressed as percentage (95% CI).
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Presence of CAC and accelerated progression were, in fact,
associated to and predictive of cardiac death or myocardial
infarction. These ﬁndings conﬁrm that the process leading to
CAC formation and progression is already acting at early
stages of CKD. In addition, it is worth noticing that cardiac
events occurred even in patients with CAC score consistent
with a low mortality risk,
31 indicating that CKD patients are
very vulnerable to the presence of CAC. The distinctive
location of calciﬁcation on coronary tree may explain the
high vulnerability of CKD patients. In this population,
calciﬁcation process develops both in intimal and medial
layer. Intimal calciﬁcation is more rupture- and erosion-prone,
causing distal emboli, with consequent acute coronary
syndromes. Medial calciﬁcation induces stiffness of coronary
wall, leading to reduction of myocardial perfusion. In
addition, medial calciﬁcation is present in peripheral arterial
tree; stiffness of these arteries reduces elastic recoil of the wall
and ultimately increases myocardial afterload with left
ventricular hypertrophy and cardiac failure.
Electron beam-computed tomography and magnetic
resonance have shown that CAC can be several millimeters
thick, occupying the full thickness of the arterial wall of
patients with renal failure; unfortunately, both procedures are
unable to distinguish the location of calciﬁcation. This
limitation also applies to MSCTemployed for CAC scoring in
the present study. Therefore, no available non-invasive-
imaging procedure is able to distinguish intimal from medial
calciﬁcation.
Fast progression of CAC has been documented in patients
on dialysis.
7–9 However, assessment of CAC progression is
regarded as not adequately powerful when follow-up is
shorter than 1 year.
32,33 In the present study, progression of
CAC score was an independent predictive factor of cardiac
events. For the ﬁrst time, therefore, an association between
CAC progression and survival has been found in CKD-
patients not on dialysis who have been followed-up for long
time.
Accelerated progression reduced survival of our patients
with a low baseline CAC score by a greater extent compared
with those with a high one. In the latter group, a worse
survival should have been expected considering that high
CAC score indicates the presence of heavily calciﬁed plaque
on coronary artery.
The data of the present study cannot provide plausible
explanations for the unexpected effect of accelerated
progression on survival in less calciﬁed CKD patients. Only
hypotheses may be advanced. Consensus exists that calciﬁca-
tion is a regulated process prompted by inﬂammation.
Inﬂammation precedes the osteogenic conversion of vascular
smooth muscle cells.
34 This initial process generates micro-
calciﬁcations in the arterial wall.
34 Calciﬁcation within the
plaque increases over time concomitantly with inﬂammation
via cytokines released by macrophages and increased
expression of alkaline phosphatase in vascular smooth muscle
cells.
35–37 In contrast to early plaque with spotty calciﬁcation,
in more advanced plaques, the progression of calciﬁcation
seems less or not at all dependent on inﬂammation; areas of
inﬂammation, in fact, decrease in advanced calciﬁed
plaques.
34,38 This ﬁnding arises the possibility that more
extended calciﬁcations are potentially less malignant because
inﬂammation is dampened.
38 Furthermore, in more calciﬁed
plaques, the prevalent role for further progression of
calciﬁcation process may be played by physiochemical
processes and absence of mineralization inhibitors.
38 Clinical
studies have shown that spotty calciﬁcation is commonly
present in soft lipid-rich plaque that is more rupture prone
and thrombogenic, and predictive of cardiovascular events
than heavy calciﬁcation.
39–43 On the basis of above points,
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Figure 2|Adjusted survival according to progression of
baseline coronary artery calcification (CAC) score.
Multivariable-adjusted (age, diabetes, GFR, and hypertension)
association between progressions of baseline CAC score (absent:
p25th percentile, continuous line; moderate: 25th–75th
percentiles, dashed line; and accelerated: 475th percentile,
dotted line). Survival was significantly (Po0.0068) worse in
patients with accelerated progression. In patients with absent
or moderate progression, survival curves overlapped. P-value
represents significance across all three groups. AU, Agatston unit
(for scoring CAC); GFR, glomerular filtration rate.
Table 2|Predictors of cardiac events by Cox regression
analysis
Independent variables HR (95% CI) P
CAC score 4100AU 8.4 (2.3–30.1) 0.001
Accelerated progression (475th percentile) 6.3 (1.5–26.2) 0.011
Diabetes 2.0 (0.8–4.9) 0.115
Interaction: CAC score 4100AU and
accelerated progression
0.08 (0.01–0.5) 0.006
Abbreviations: AU, Agatston unit; CAC, coronary artery calcification; CI, confidence
interval; HR, hazard risk.
Among all potential confounders (see ‘Materials and Methods’ and ‘Results’), only
diabetes reached a P-valueo0.20 and entered into multiple Cox regression analysis.
Baseline CAC score 4100AU and accelerated CAC score progression (475th
percentile) independently predicted cardiac death or myocardial infarction.
Baseline CAC score 4100AU and accelerated progression (475th percentile)
significantly interacted and reduced the HR for cardiac events (0.08 (0.01–0.5)).
In patients with CAC score 4100AU and accelerated progression, HR was 4.2
(as a result of 8.4 6.3 0.08); this HR was lower than that of each variable.
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was a sign of prevailing soft lipid-rich plaque with more
active inﬂammatory processes; progression occurring in a
still inﬂamed and unstable plaque might have reduced
survival. In contrast, high baseline CAC score was likely a
sign of stable plaque with less active or absent inﬂammatory
lesions, and the progression in this plaque might have
occurred by factors other than inﬂammation with minor
impact on survival.
It is important to underline that higher baseline CAC
score and accelerated progression interacted signiﬁcantly
despite they were independently associated to cardiac
events; because of this interaction, the risk of events was
lower than that predicted by each variable. This interaction
is, in our opinion, relevant and should be taken into
account for reliable evaluation of data from trials assessing
the association between extent, progression of CAC and
events.
Despite major societies recommend CAC assessment for
stratiﬁcation of cardiovascular risk,
44 the usefulness of
screening asymptomatic patients for CAC has been recently
disputed because data on potential association between CAC
score and outcomes are regarded as not adequately robust,
especially in low-risk patients.
32,33,45 Likely, this opinion is
not appropriate for CKD patients. CKD itself increases the
likelihood of cardiac event; therefore, CKD patients are
already at intermediate risk. Screening for presence of CAC
may be appropriate in CKD patients who are reallocated in
high risk of coronary event by any degree of CAC. The data of
the present study may support this view.
In conclusion, in CKD patients, an association is present
between extent of CAC and cardiac events; progression of
calciﬁcation process is an independent predictive factor of
cardiac events with prevailing negative impact on survival of
less calciﬁed patients; the assessment of both baseline CAC
score and its progression might be useful for cardiovascular
risk stratiﬁcation and guiding decisions for the prevention of
cardiac outcomes. Larger trials focusing on combined effects
of baseline CAC score and its progression on cardiac events
are mandatory.
MATERIALS AND METHODS
The protocol was approved by the local institutional review board.
Consecutive male and not pregnant female outpatients receiving
care at the Department of Nephrology of University ‘Federico II’,
Naples (Italy), screened for CAC from January 2003 to December
2006, entered the study after they had signed informed consent.
Inclusion criteria were: ageX18 years, CKD stages 2–5 (GFR: 1.48 to
40.25ml/s) not requiring dialysis treatment, no less than 6-month
follow-up before the enrollment, and at least two CAC-score
assessments before the occurrence of cardiac event or closing of
study. Exclusion criteria were: symptoms of heart failure and/or
coronary artery disease, previous history of myocardial infarction,
coronary bypass surgery, angioplasty, stroke, arrhythmia (that would
impede assessment of CAC score with MSCT), and rapidly
progressive renal disease. Diabetic patients were those on regular
use of insulin or oral hypoglycemic drugs.
Routine blood chemistry and serum concentrations of calcium,
phosphorus, intact parathyroid hormone, homocysteine, C-reactive
protein, triglycerides, total cholesterol, and high-density lipoprotein
cholesterol were serially measured. These variables were assessed at
the enrollment and every 6 and 3 months in patients with CKD
stages 2–3 (GFR: 1.48–0.5ml/s) and CKD stages 4–5 (GFR:
0.48–o0.25ml/s), respectively. Results were averaged for statistical
analysis. Low-density lipoprotein cholesterol was calculated using
the Friedewald equation. GFR was given by 24-h-measured
creatinine clearance. Intact parathyroid hormone was assayed by
chemiluminescent immunometric method (Diagnostic Products,
Los Angeles, CA) and high-sensitivity C-reactive protein by
immunoturbidimetric method.
Cardiac death and myocardial infarction were regarded
as outcome and assigned by a blinded cardiologist. Screening of
CAC was performed by MSCT and CAC score measured as AU.
CAC score was obtained at the entry into the study (baseline CAC
score) and every 12 months. To calculate the annual progression of
CAC score that accounts for the time between scans, the following
formula was used: last CAC score baseline CAC score/days of
follow-up 365 (ref. 46). In patients who experienced a cardiac
event, the CAC score assessed before the event was assumed as
the last; in other patients, the last CAC score was performed at
the closing of the study. The annual progression of CAC score was
categorized as follows: absent (p25th percentile), moderate (25th–75th
percentiles), and accelerated (475th percentile). Scans were analyzed
by two radiologists (MS and ML) who were unaware of the patient’s
clinical characteristics and previous MSCT scoring.
Patients were classiﬁed in two groups according to baseline CAC
score (p100 and 4100AU). The CAC score of 100AU was chosen
as cutoff because it predicted coronary heart disease-related events
47
and provided evidence of obstructive coronary artery disease
48 in
symptomatic patients undergoing angiography; in asymptomatic
subjects, it was the threshold that was able to identify deﬁnite to
extensive plaque burden and patients with moderately high to very
high cardiovascular risk.
31
During the follow-up, clinicians did not take into account the
result of CT scan; changes in lifestyle or medication use were based
on clinical condition and blood chemistry.
Scans were performed using an Aqualon 64-slice MSCT scanner
(Toshiba Medical Systems; Tokyo, Japan). Unenhanced calcium
scoring scan was obtained with the following protocol: retrospective
ECG gating; tube voltage 120kV; tube current 180mAs; rotation
time 330ms; detector collimation 24 1.2mm; reconstructed slice
thickness 3.0mm; and pitch 0.2. The scan range extended from the
level of the carina to just below the diaphragm. The ﬁeld of view was
adjusted according to the size of the heart. CT data sets were
subsequently transferred to a workstation: 3-D line Vitrea work-
station (Vital Images; Plymouth, MN). Calcium score was
performed using a semi automated threshold-dependent algorithm.
Calciﬁcations within the coronary artery tree above a threshold of
130 HU were included. Calciﬁcations present in each coronary
artery (left main, left anterior descending, diagonal branches,
circumﬂex, obtuse marginal branches, right coronary, acute margin-
al branches, posterior descending artery, and posterior lateral
segmental branches) were scored and summed to obtain the CAC
score.
Data are shown as percentage (95% CIs) for categorical variables
and as median (IQR) for continuous or discrete variables.
The Kaplan–Meier survival analysis was performed to compare
survival curves of patients divided according to baseline CAC score
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survival curves. For group comparisons, multinomial logistic
regression was performed for comparison of proportions and its
95% CIs were computed by a bootstrap resampling procedure (50
times). The Mann–Whitney U-test was used as non-parametric test
for comparison of medians. The Cox regression analysis was
performed to ﬁnd the model that best predicted the combined
outcome (cardiac death and myocardial infarction) using fractional
polynomial regression to study the relationship between continuous
and discrete variables and outcome. All the variables reported in
Table 1 were considered, and only those that reached a P-value level
o0.20 at univariate analysis were included and reported in the
multivariate Cox regression model.
Interaction between baseline CAC score and its progression was
also analyzed because stratiﬁcation by both factors pointed out a
possible effect modiﬁcation with statistically signiﬁcant Cox
regression-based test for equality of survival curves. Afterward,
annualized progression was dichotomized using the 75th percentile
value (below and above or equal) because only accelerated progres-
sion was strongly informative in the ﬁnal model. Finally, Jackknife
procedure was used to validate the best-ﬁt regression model and
compute standard errors. STATA/SE, version 9.2 for Windows (Stata
Corp, College Station, TX), was used to analyze the data.
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